



Solos Endoscopy, Inc.
www.solosendoscopy.com
(OTCPK: SNDY)

November 12, 2009

Dear Shareholders,

I am very pleased to be able to communicate with our loyal shareholders directly and to give you an update on our impressive progress to date.

Solos Endoscopy, Inc. has been at the forefront of breakthrough medical devices and technologies for the treatment and management of diseases for over 20 years. The Company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques.

The company has successfully completed the Food and Drug Administration (FDA) Level II Baseline Inspection in which it received a NAI (No Action Indicated) for the inspection. It is standard for the FDA to perform unannounced inspections periodically for medical device manufacturers, and the successful inspection by the FDA validates the Company's quality system and its strict adherence to that system.

In addition to the FDA approval for our product line, the Company has taken the initial steps to obtain the CE Mark for its MammoView™ line of surgical endoscopy instruments. This will allow the MammoView™ line to be sold throughout the European Economic Union (EEU), which according to a 2009 report published by Frost & Sullivan represents \$94 Billion, or 30%, of the worldwide demand for medical instruments.

Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease. These products will allow the physician to examine organs and tissues within the body without the need for intrusive surgery. The Company is currently marketing its next generation breast endoscopy system, the MammoView™ system, for early breast cancer detection.

Recently, the company has received multiple new purchase orders for its MammoView™ line of surgical endoscopy instruments from approximately 30 hospitals, which Solos has added to their client base over the last 12 months. More than half of the purchase orders are coming from teaching hospitals affiliated with prestigious public and private Universities across the Country .


Solos' main focus is to strengthen the Company's market share in the industry. Solos is implementing several strategies to accomplish this goal. The Company plans on working towards the international launch of its product lines as it continues to strengthen its national distribution channels in the United States. In addition, Solos has plans to

continue building market awareness for the Company and its products, attracting key employees and building its sales and distribution network.

On November 5, 2009, it was announced that the Company retained the services of Advertising Associates International to manage its 2010 marketing, promotional and advertising campaign. The AAI team, which is comprised of marketing, creative and technical specialists as well as consultants drawn from the medical, engineering and dental professions, has been highly regarded in the marketing field for forty-five years.

In closing, I want to thank each of you for your patience and continued support of Solos. I encourage you to contact our Investor Relations firm, Big Apple Consulting USA at (407) 389-5900, regarding any questions you might have about the Company. Please submit your email address to receive email updates, whenever a press release is published. To view more information about the Company and its products visit www.solosendoscopy.com.

Regards,



Robert Segersten
President and CEO
Solos Endoscopy, Inc.

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.